Adcentrx raises funds to advance ADCs into clinical development
26 Apr 2023
ADCPhase 1
Preview
Source: Pharmaceutical Technology
Adcentrx is focused on developing protein conjugate therapeutics to treat cancer and other life-threatening diseases. Credit: National Cancer InstituteCancer Institute on Unsplash.
Biotechnology company Adcentrx Therapeutics has raised $38m in Series A+ financing to advance its pipeline of new antibody-drug conjugate (ADC) therapeutics into clinical development.
Lighthouse Capital and Life Venture Partners served as financial advisors to the company.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsVascular Endothelial Growth Factor (VEGF) Drugs in Development by Therapy Areas and Indications, ... GlobalData
Preview
Source: Pharmaceutical Technology
ReportsTransforming Growth Factor (TGF) Drugs in Development by Therapy Areas and Indications, Stages, M... GlobalData
View all
Led by Eight Roads Ventures, the financing round saw participation from strategic investors, including the Trinity Innovation Fund, ABio-X, Delta Capital and F-Prime Capital.
Adcentrx Therapeutics is focused on developing protein conjugate therapeutics to treat cancer and other life-threatening diseases.
It works to develop advanced targeted therapeutics to improve patient treatment options by combining the targeting precision of biologics and the small molecule payloads’ disease-fighting power.
ADRX-070 is the company’s lead candidate and is anticipated to enter a first-in-human Phase I clinical trial in the second half of 2023.
The company is developing other candidates and intends to advance at least one into clinical development each year.
Adcentrx Therapeutics founder and CEO Hui Li said: “Over the last two years, we have made significant progress advancing our emerging therapeutic pipeline that implements our proprietary and differentiated technology platform.
“This new round of funding from our investors will enable Adcentrx to quickly advance our safer and more efficacious conjugate therapies for patients in need.
“This year will be pivotal for Adcentrx, when we transition from the discovery stage into a clinical-stage company.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.